ERBB2 and breast cancer: Compared with Luminal A, Luminal B and HER2(+) breast cancer subtypes, patients with TNBC were always recognized to have the worst overall survival data due to its rapid progression, high probabilities of early recurrence, and distant metastasis resistant to standard treatment (33).